Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Anemia is prevalent in cardiovascular disease (CVD) and associated with increased morbidity and mortality.
• The role of anemia as a disease marker versus a modifiable factor in CVD is under investigation.

Purpose of the Study:

• To review current evidence on iron supplementation, erythropoiesis-stimulating agents (ESAs), and blood transfusions for anemia in CVD.
• To assess the impact of these therapies on morbidity, mortality, and quality of life.

Main Methods:

• Systematic review of recent clinical evidence.
• Analysis of treatment outcomes including patient-reported symptoms, exercise capacity, re-hospitalization rates, and mortality.

Main Results:

• Intravenous ferric carboxymaltose (FC) improved symptoms, exercise capacity, and reduced re-hospitalization in heart failure (HF) patients.
• Darbepoetin alfa showed improved quality of life scores but increased adverse events in HF.
• Blood transfusions for anemia (Hg < 10 g/dL) did not improve outcomes in CVD.
• No mortality benefits were observed for FC or darbepoetin in HF.

Conclusions:

• Anemia in CVD may serve as a marker of disease severity rather than a direct target for modification.
• Iron supplementation and ESAs may improve quality of life in anemic HF patients, but not mortality.
• Further research is needed to clarify the role of these therapies in CVD, particularly in coronary artery disease.